Landscape Capital Management L.L.C. Buys New Position in CeriBell, Inc. $CBLL

Landscape Capital Management L.L.C. purchased a new position in shares of CeriBell, Inc. (NASDAQ:CBLL) during the 2nd quarter, HoldingsChannel.com reports. The institutional investor purchased 106,819 shares of the company’s stock, valued at approximately $2,078,000.

Several other large investors have also modified their holdings of the company. Strs Ohio purchased a new position in shares of CeriBell during the first quarter worth approximately $27,000. Caitong International Asset Management Co. Ltd raised its position in CeriBell by 3,971.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock valued at $28,000 after purchasing an additional 1,231 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in CeriBell during the 3rd quarter worth $33,000. CWM LLC boosted its stake in CeriBell by 1,178.5% during the 4th quarter. CWM LLC now owns 1,841 shares of the company’s stock worth $40,000 after purchasing an additional 1,697 shares during the period. Finally, Tower Research Capital LLC TRC grew its position in CeriBell by 353.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock worth $43,000 after purchasing an additional 1,801 shares during the last quarter.

Key CeriBell News

Here are the key news stories impacting CeriBell this week:

• Positive Sentiment: Analyst price targets increased. BTIG Research raised its target from $28 to $30 and reiterated a Buy rating, while Canaccord Genuity lifted its target from $25 to $26 and also maintained a Buy rating. These revisions indicate continued confidence in CeriBell’s growth prospects. CeriBell Stock Price Expected to Rise, BTIG Research Analyst Says
• Positive Sentiment: Institutional interest has been supportive. TimesSquare Capital Management initiated a position valued at approximately $15.2 million, while KCM Capital increased its holdings by 40% to 1.4 million shares. Additional firms also established or expanded positions, suggesting some professional investors see value in CBLL.
• Neutral Sentiment: Recent financial results were mixed. CeriBell’s quarterly revenue of $28.1 million exceeded the $27.28 million consensus estimate, but its $0.51 per-share loss was wider than the expected $0.47 loss. The company remains unprofitable, and analysts expect a full-year loss of approximately $1.96 per share.
• Neutral Sentiment: Analyst opinion remains generally favorable but valuation expectations are uneven. The consensus rating is “Moderate Buy,” although the average target of $22.40 is below the recent trading level. Barclays upgraded the stock to Neutral, reflecting a more cautious stance.
• Negative Sentiment: Senior executives sold a substantial number of shares. CEO Xingjuan Chao sold 33,614 shares for about $841,000 across August 18–19, reducing her holdings by roughly 4%. CFO Scott Blumberg sold 34,502 shares for approximately $864,000, cutting his direct ownership by about 18.45%. The transactions occurred around $25 per share, close to CeriBell’s 52-week high, and could be interpreted as profit-taking or a potential near-term confidence signal. CeriBell Insider Trading Activity

CeriBell Trading Down 0.5%

Shares of CeriBell stock opened at $24.20 on Friday. The firm has a market cap of $928.80 million, a price-to-earnings ratio of -13.75 and a beta of 0.81. CeriBell, Inc. has a 52-week low of $10.85 and a 52-week high of $25.33. The company’s 50-day simple moving average is $19.54 and its 200-day simple moving average is $19.22. The company has a quick ratio of 8.79, a current ratio of 9.18 and a debt-to-equity ratio of 0.16.

CeriBell (NASDAQ:CBLL) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). CeriBell had a negative net margin of 64.73% and a negative return on equity of 44.85%. The firm had revenue of $28.10 million during the quarter, compared to analyst estimates of $27.28 million. As a group, equities research analysts anticipate that CeriBell, Inc. will post -1.96 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have commented on the stock. Canaccord Genuity Group lifted their price objective on shares of CeriBell from $25.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. Barclays upgraded shares of CeriBell to a “neutral” rating in a research note on Tuesday. BTIG Research boosted their price target on CeriBell from $28.00 to $30.00 and gave the company a “buy” rating in a research report on Tuesday, August 18th. Finally, Weiss Ratings raised CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 13th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, CeriBell has a consensus rating of “Moderate Buy” and a consensus target price of $22.40.

Insider Buying and Selling at CeriBell

In related news, CFO Scott Blumberg sold 33,512 shares of the company’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $25.03, for a total transaction of $838,805.36. Following the transaction, the chief financial officer owned 148,121 shares of the company’s stock, valued at $3,707,468.63. This represents a 18.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Joseph Michael Taylor sold 13,095 shares of the stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $23.40, for a total value of $306,423.00. Following the completion of the transaction, the director owned 48,478 shares of the company’s stock, valued at $1,134,385.20. The trade was a 21.27% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 369,286 shares of company stock worth $7,718,927. 17.70% of the stock is currently owned by company insiders.

CeriBell Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.